Compare Stocks: RXST, CERS, EMBC, and SMTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.30 +0.9%	$2.55	$1.38 ▼ $3.47	$463.51M	1.83	1.94 million shs	787,964 shs
EMBC Embecta	$5.68 -1.2%	$5.22	$2.77 ▼ $14.91	$322.11M	0.84	1.06 million shs	583,083 shs
RXST RxSight	$4.81 -0.8%	$5.90	$4.48 ▼ $13.22	$200.06M	1.15	780,827 shs	521,936 shs
SMTI Sanara MedTech	$35.07 +0.1%	$34.71	$16.05 ▼ $35.34	$322.22M	1.19	178,202 shs	123,980 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	0.00%	+0.88%	-6.50%	-26.28%	+36.90%
EMBC Embecta	0.00%	+0.53%	+16.16%	+75.31%	-58.90%
RXST RxSight	0.00%	+2.78%	-19.30%	-2.83%	-41.41%
SMTI Sanara MedTech	0.00%	+0.63%	+0.11%	+47.23%	+8.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.30 +0.9%	$2.55	$1.38 ▼ $3.47	$463.51M	1.83	1.94 million shs	787,964 shs
EMBC Embecta	$5.68 -1.2%	$5.22	$2.77 ▼ $14.91	$322.11M	0.84	1.06 million shs	583,083 shs
RXST RxSight	$4.81 -0.8%	$5.90	$4.48 ▼ $13.22	$200.06M	1.15	780,827 shs	521,936 shs
SMTI Sanara MedTech	$35.07 +0.1%	$34.71	$16.05 ▼ $35.34	$322.22M	1.19	178,202 shs	123,980 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	0.00%	+0.88%	-6.50%	-26.28%	+36.90%
EMBC Embecta	0.00%	+0.53%	+16.16%	+75.31%	-58.90%
RXST RxSight	0.00%	+2.78%	-19.30%	-2.83%	-41.41%
SMTI Sanara MedTech	0.00%	+0.63%	+0.11%	+47.23%	+8.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERS Cerus	2.40	Hold	$5.25	128.26% Upside
EMBC Embecta	1.60	Reduce	$11.00	93.66% Upside
RXST RxSight	1.92	Reduce	$8.17	69.90% Upside
SMTI Sanara MedTech	1.80	Reduce	$35.00	-0.20% Downside

Current Analyst Ratings Breakdown

Latest RXST, CERS, EMBC, and SMTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	EMBC Embecta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/22/2026	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$6.50 ➝ $5.75
9/22/2026	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$6.50 ➝ $5.50
9/14/2026	CERS Cerus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	RXST RxSight	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/20/2026	CERS Cerus	Freedom Broker Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.50
8/11/2026	SMTI Sanara MedTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$8.00 ➝ $7.00
8/6/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$5.50 ➝ $6.30
8/3/2026	EMBC Embecta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/3/2026	SMTI Sanara MedTech	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERS Cerus	$206.13M	2.25	N/A	N/A	$0.34 per share	6.76
EMBC Embecta	$1.08B	0.30	$4.00 per share	1.42	($11.12) per share	-0.51
RXST RxSight	$134.48M	1.49	N/A	N/A	$6.70 per share	0.72
SMTI Sanara MedTech	$103.12M	3.13	$0.59 per share	58.98	$0.67 per share	52.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	11/5/2026 (Estimated)
EMBC Embecta	$95.40M	$1.48	3.84	3.23	N/A	8.59%	-19.25%	10.82%	11/24/2026 (Estimated)
RXST RxSight	-$38.94M	-$1.13	N/A	N/A	N/A	-36.80%	-17.35%	-14.70%	11/4/2026 (Estimated)
SMTI Sanara MedTech	-$37.56M	-$3.59	N/A	N/A	N/A	-29.15%	29.72%	2.84%	11/11/2026 (Estimated)

Latest RXST, CERS, EMBC, and SMTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CERS Cerus	-$0.0125	N/A	N/A	N/A	$63.25 million	N/A
11/4/2026	Q3 2026	RXST RxSight	-$0.29	N/A	N/A	N/A	$27.19 million	N/A
8/11/2026	Q2 2026	SMTI Sanara MedTech	-$0.0250	-$0.05	-$0.0250	-$0.05	$28.95 million	$28.14 million
8/7/2026	Q3 2026	EMBC Embecta	$0.2658	$0.56	+$0.2942	$0.36	$254.53 million	$271.70 million
8/5/2026	Q2 2026	RXST RxSight	-$0.3294	-$0.29	+$0.0394	-$0.29	$32.55 million	$33.74 million
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERS Cerus	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.04	0.70%	N/A	2.70%	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Latest RXST, CERS, EMBC, and SMTI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2026	EMBC Embecta	quarterly	$0.01	0.8%	8/27/2026	8/27/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERS Cerus	0.49	1.83	1.07
EMBC Embecta	N/A	1.68	1.17
RXST RxSight	N/A	4.07	3.61
SMTI Sanara MedTech	5.86	2.58	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERS Cerus	78.37%
EMBC Embecta	93.83%
RXST RxSight	78.78%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
CERS Cerus	5.30%
EMBC Embecta	1.30%
RXST RxSight	10.05%
SMTI Sanara MedTech	42.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERS Cerus	345	201.52 million	190.84 million	Optionable
EMBC Embecta	1,850	56.66 million	55.92 million	Optionable
RXST RxSight	461	41.59 million	37.41 million	Optionable
SMTI Sanara MedTech	108	9.19 million	5.33 million	Not Optionable

RXST, CERS, EMBC, and SMTI Headlines

Recent News About These Companies

Head-To-Head Comparison: Kewaunee Scientific (NASDAQ:KEQU) versus Sanara MedTech (NASDAQ:SMTI)

October 6, 2026 | americanbankingnews.com

Comparing Profound Medical (NASDAQ:PROF) and Sanara MedTech (NASDAQ:SMTI)

October 6, 2026 | americanbankingnews.com

Sanara MedTech stock gains after shareholders approve merger

October 5, 2026 | ad-hoc-news.deA

Sanara MedTech Inc. (NASDAQ:SMTI) Receives Average Rating of "Reduce" from Analysts

October 1, 2026 | americanbankingnews.com

Sanara MedTech stock faces a merger vote after Q2 loss

September 29, 2026 | ad-hoc-news.deA

Sanara MedTech Inc. (NASDAQ:SMTI) Stock Has Consensus Target Price of $35.00 According to Brokerages

September 26, 2026 | marketbeat.com

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

September 10, 2026 | businesswire.com

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Sanara MedTech Inc

August 14, 2026 | money.usnews.com

Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates

August 11, 2026 | zacks.com

Sanara MedTech Inc. (SMTI) Releases Q2 2026 Earnings: Revenue Rises 8.9%

August 11, 2026 | quiverquant.comQ

Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)

August 11, 2026 | globenewswire.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

August 6, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

August 4, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)

August 4, 2026 | globenewswire.com

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

August 3, 2026 | businesswire.com

MiMedx to acquire Sanara MedTech for $350M

July 31, 2026 | massdevice.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)

July 30, 2026 | prnewswire.com

July 30, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders

July 30, 2026 | prnewswire.com

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

July 30, 2026 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RXST, CERS, EMBC, and SMTI Company Descriptions

Cerus NASDAQ:CERS

$2.30 +0.02 (+0.88%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.30 0.00 (-0.22%)

As of 10/9/2026 07:30 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Embecta NASDAQ:EMBC

$5.68 -0.07 (-1.22%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.80 +0.12 (+2.06%)

As of 10/9/2026 07:57 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

RxSight NASDAQ:RXST

$4.81 -0.04 (-0.82%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.77 -0.04 (-0.91%)

As of 10/9/2026 07:55 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Sanara MedTech NASDAQ:SMTI

$35.07 +0.02 (+0.06%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$35.07 0.00 (0.00%)

As of 10/9/2026 04:19 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXST, CERS, EMBC, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXST, CERS, EMBC, and SMTI Earnings

Compare Dividends

Latest RXST, CERS, EMBC, and SMTI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXST, CERS, EMBC, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RXST, CERS, EMBC, and SMTI Company Descriptions

Cerus NASDAQ:CERS

Embecta NASDAQ:EMBC

RxSight NASDAQ:RXST

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools